Stock A214450 PHARMARESEARCH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

PharmaResearch Co., Ltd. Stock

Equities

A214450

KR7214450009

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
139,600 KRW +8.55% Intraday chart for PharmaResearch Co., Ltd. +17.51% +27.49%
2023 PharmaResearch Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2021 PHARMA RESEARCH BIO Co., Ltd. announced that it has received KRW 30 billion in funding from PharmaResearch Co., Ltd. CI

Financials

Sales 2024 * 304B 223M Sales 2025 * 346B 254M Capitalization 1,435B 1.05B
Net income 2024 * 100B 73.4M Net income 2025 * 117B 85.88M EV / Sales 2024 * 4.16 x
Net cash position 2024 * 169B 124M Net cash position 2025 * 294B 215M EV / Sales 2025 * 3.3 x
P/E ratio 2024 *
14.4 x
P/E ratio 2025 *
12.3 x
Employees 354
Yield 2024 *
0.6%
Yield 2025 *
0.65%
Free-Float 60.05%
More Fundamentals * Assessed data

Chart PharmaResearch Co., Ltd.

Dynamic Chart

Latest news about PharmaResearch Co., Ltd.

PharmaResearch Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PHARMA RESEARCH BIO Co., Ltd. announced that it has received KRW 30 billion in funding from PharmaResearch Co., Ltd. CI
PHARMA RESEARCH BIO Co., Ltd. announced that it expects to receive KRW 30 billion in funding from PharmaResearch Co., Ltd. CI
PharmaResearch Co., Ltd. acquired Medicoson Co., Ltd. CI
PharmaResearch Co., Ltd. announced that it has received KRW 25 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm CI
PharmaResearch Co., Ltd. announced that it expects to receive KRW 25 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019. CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019. CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019. CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019. CI
Pharma Research Products Co., Ltd's Equity Buyback announced on February 21, 2019, has expired with 129,237 shares, representing 1.37% for KRW 4,992.18 million. CI
Pharma Research Products Co., Ltd's Equity Buyback Plan Extended till February 21, 2020. CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019. CI
Pharma Research Products Co., Ltd announces an Equity Buyback for KRW 5,000 million worth of its shares. CI
Pharma Research Products Co., Ltd authorizes a Buyback Plan. CI
More news

Press releases PharmaResearch Co., Ltd.

PharmaResearch acquires patent registration on bone grafting composition in China AQ
High Concentration Nucleic Acid Liquid Composition Patent Registration is Confirmed in Japan AQ
PharmaResearch Participates in South Korea's Largest Medical Exhibition - KIMES 2022 AQ
PharmaResearch acquires a patent for filler composition for molding filling composition for tissue enhancement AQ
PharmaResearch Acquires Medicoson, Medical Electronics Company AQ
More press releases

Quotes and Performance

1 day+8.55%
1 week+17.51%
Current month+9.40%
1 month+27.02%
3 months+37.81%
6 months+17.81%
Current year+27.49%
More quotes

Highs and lows

1 week
121 600.00
Extreme 121600
143 000.00
1 month
107 000.00
Extreme 107000
143 000.00
Current year
86 800.00
Extreme 86800
143 000.00
1 year
86 800.00
Extreme 86800
158 200.00
3 years
55 000.00
Extreme 55000
158 200.00
5 years
29 700.00
Extreme 29700
158 200.00
10 years
29 700.00
Extreme 29700
158 200.00
More quotes

Managers and Directors - PharmaResearch Co., Ltd.

Managers TitleAgeSince
Ki-Seok Kang CEO
 Chief Executive Officer 48 00-01-31
Shin-Kyou Kim CEO
 Chief Executive Officer 59 -
Sang-Soo Jung CHM
 Chairman 66 -
Members of the board TitleAgeSince
Shin-Kyou Kim CEO
 Chief Executive Officer 59 -
Sang-Soo Jung CHM
 Chairman 66 -
Ki-Seok Kang CEO
 Chief Executive Officer 48 00-01-31
More insiders

ETFs positioned on PharmaResearch Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ +2.11% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.67% -
More ETFs positioned on PharmaResearch Co., Ltd.

Quotes

Date Price Change Volume
24-05-03 139,600 +8.55% 410,834
24-05-02 128,600 +0.78% 158,062
24-04-30 127,600 -0.70% 224,106
24-04-29 128,500 +8.16% 370,483
24-04-26 118,800 +4.85% 190,974

End-of-day quote Korea S.E., May 02, 2024

More quotes

Company Profile

PharmaResearch Co Ltd, formerly Pharma Research Products Co Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company produces and sells regenerated products such as pharmaceuticals, medical devices, and cosmetics. In addition, the Company is involved in the venture investment and real estate leasing. The Company mainly provides its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-09 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for PharmaResearch Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
139,600 KRW
Average target price
175,000 KRW
Spread / Average Target
+25.36%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
PHARMARESEARCH CO., LTD. Stock PharmaResearch Co., Ltd.
+27.49% 1.06B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.45% 40.51B
BIOGEN INC. Stock Biogen Inc.
-15.94% 31.67B
UCB Stock UCB
+52.66% 24.62B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.50% 15.65B
INCYTE CORPORATION Stock Incyte Corporation
-14.38% 12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.81B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-4.33% 8.5B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A214450 Stock